On the sensitivity of α/β prediction to dose calculation methodology in prostate brachytherapy

International Journal of Radiation Oncology Biology Physics

Volumn 88, Issue 2, 2014, Pages 345-350

  Afsharpour, Hossein ^a,b   Walsh, Sean ^c,d   Collins Fekete, Charles Antoine ^a   Vigneault, Eric ^a   Verhaegen, Frank ^c,e   Beaulieu, Luc ^a  

^a LAVAL UNIVERSITY   (Canada)

^b HÔPITAL CHARLES LEMOYNE   (Canada)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASES; MONTE CARLO METHODS; ONCOLOGY; PARAMETER ESTIMATION; SENSITIVITY ANALYSIS; UROLOGY;

BIOLOGICALLY EFFECTIVE DOSE; DOSE CALCULATION; DOSE DISTRIBUTIONS; EXTERNAL BEAM RADIATION THERAPY; LEVELS OF DETAIL; METHODS AND MATERIALS; PROSTATE BRACHYTHERAPY; RADIOSENSITIVITY PARAMETERS;

RADIOTHERAPY;

IODINE 125;

ALPHA BETA RATIO; ARTICLE; BRACHYTHERAPY; CANCER RADIOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DOSIMETRY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; MAJOR CLINICAL STUDY; MEASUREMENT ACCURACY; MONOTHERAPY; MONTE CARLO METHOD; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE DISTRIBUTION; RADIOLOGICAL PARAMETERS; RADIOSENSITIVITY; SENSITIVITY ANALYSIS;

ALGORITHMS; BRACHYTHERAPY; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; MALE; MONTE CARLO METHOD; PROSTATIC NEOPLASMS; RADIATION TOLERANCE; RADIOTHERAPY DOSAGE; REFERENCE VALUES; RELATIVE BIOLOGICAL EFFECTIVENESS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84891873253     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2013.11.001     Document Type: Article

References (34)

1. S.M. Oliveira, N.J. Teixeira, and L. Fernandes What do we know about the α/β for prostate cancer? Med Phys 39 2012 3189 3201
2. D.J. Brenner, and E.J. Hall Fractionation and protraction for radiotherapy of prostate carcinoma Int J Radiat Oncol Biol Phys 43 1999 1095 1101 (Pubitemid 29144800)
3. C.R. King, and C.S. Mayo Is the prostate alpha/beta ratio of 1.5 from Brenner and Hall a modeling artifact? Int J Radiat Oncol Biol Phys 47 2000 536 538
4. D.J. Brenner, and E.J. Hall In response to Drs. King and Mayo: Low α/β values for prostate appear to be independent of modeling details Int J Radiat Oncol Biol Phys 47 2000 538 539
5. C.R. King, and J.F. Fowler A simple analytic derivation suggests that prostate cancer alpha/beta ratio is low Int J Radiat Oncol Biol Phys 51 2001 213 214 (Pubitemid 32758881)
6. J. Fowler, R. Chappell, and M. Ritter Is alpha/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys 50 2001 1021 1031 (Pubitemid 32594841)
7. D.J. Brenner, A.A. Martinez, and G.K. Edmundson et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue Int J Radiat Oncol Biol Phys 52 2002 6 13 (Pubitemid 34041562)
8. J.Z. Wang, M. Guerrero, and X.A. Li How low is the alpha/beta ratio for prostate cancer? Int J Radiat Oncol Biol Phys 55 2003 194 203 (Pubitemid 36020360)
9. A.E. Nahum, B. Movsas, and E.M. Horwitz et al. Incorporating clinical measurements of hypoxia into tumor local control modeling of prostate cancer: Implications for the alpha/beta ratio Int J Radiat Oncol Biol Phys 57 2003 391 401 (Pubitemid 37040935)
10. J.Z. Wang, and X.A. Li Evaluation of external beam radiotherapy and brachytherapy for localized prostate cancer using equivalent uniform dose Med Phys 30 2003 34 40 (Pubitemid 36106005)
11. J.Z. Wang, and X.A. Li Impact of tumor repopulation on radiotherapy planning Int J Radiat Oncol Biol Phys 61 2005 220 227 (Pubitemid 40039126)
12. J.Z. Wang, N.A. Mayr, and S. Nag et al. Effect of edema, relative biological effectiveness, and dose heterogeneity on prostate brachytherapy Med Phys 33 2006 1025 1032
13. R. Nath, W.S. Bice, and W.M. Butler et al. AAPM recommendations on dose prescription and reporting methods for permanent interstitial brachytherapy for prostate cancer: Report of Task Group 137 Med Phys 36 2009 5310 5322
14. J.F. Fowler, A.E. Nahum, and C.G. Orton The best radiotherapy for the treatment of prostate cancer involves hypofractionation Med Phys 33 2006 3081 3084 (Pubitemid 44327407)
15. M. Carlone, D. Wilkins, and B. Nyiri et al. TCP isoeffect analysis using a heterogeneous distribution of radiosensitivity Med Phys 31 2004 1176 1182 (Pubitemid 38656790)
16. M. Carlone, D. Wilkins, and B. Nyiri et al. Comparison of alpha/beta estimates from homogeneous (individual) and heterogeneous (population) tumor control models for early stage prostate cancer Med Phys 30 2003 2832 2848 (Pubitemid 37266779)
17. V. Macias, and A. Biete Hypofractionated radiotherapy for localised prostate cancer. Review of clinical trials Clin Transl Oncol 11 2009 437 445
18. P.E. Lindsay, V.V. Moiseenko, and J.V. Dyk et al. The influence of brachytherapy dose heterogeneity on estimates of alpha/beta for prostate cancer Phys Med Biol 48 2003 507 522 (Pubitemid 36322042)
19. M.J. Rivard, J.L.M. Venselaar, and L. Beaulieu The evolution of brachytherapy treatment planning Med Phys 36 2009 2136 2153
20. L. Beaulieu, A.C. Tedgren, and J.F. Carrier et al. Report of the Task Group 186 on model-based dose calculation methods in brachytherapy beyond the TG-43 formalism: Current status and recommendations for clinical implementation Med Phys 39 2012 6208 6236
21. J.F. Carrier, L. Beaulieu, and F. Therriault-Proulx et al. Impact of interseed attenuation and tissue composition for permanent prostate implants Med. Phys 33 2006 595 604
22. R. Dale, and B. Jones The clinical radiobiology of brachytherapy Br J Radiol 71 1998 465 483 (Pubitemid 28243066)
23. R.G. Stock, N.N. Stone, and Y.C. Lo et al. Postimplant dosimetry for 125I prostate implants: Definitions and factors affecting outcome Int J Radiat Oncol Biol Phys 48 2000 899 906
24. L. Potters, Y. Cao, and E. Calugaru et al. A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy Int J Radiat Oncol Biol Phys 50 2001 605 614 (Pubitemid 32519593)
25. R.G. Stock, N.N. Stone, and J.A. Cesaretti et al. Biologically effective dose values for prostate brachytherapy: Effects on PSA failure and posttreatment biopsy results Int J Radiat Oncol Biol Phys 64 2006 527 533 (Pubitemid 43083442)
26. E.F. Miles, J.W. Nelson, and A.K. Alkaissi et al. Biologically effective dose (BED) correlation with biochemical control after low-dose rate prostate brachytherapy for clinically low-risk prostate cancer Int J Radiat Oncol Biol Phys 77 2010 139 146
27. N.N. Stone, R.G. Stock, and J.A. Cesaretti et al. Local control following permanent prostate brachytherapy: Effect of high biologically effective dose on biopsy results and oncologic outcomes Int J Radiat Oncol Biol Phys 76 2010 355 360
28. W.M. Butler, R.R. Stewart, and G.S. Merrick Evaluation of radiobiologic biochemical control in a large permanent prostate brachytherapy population from a single institution using AAPM TG-137 parameters Brachytherapy 10 2011 16 28
29. O. Zebentout, R. Apardian, and L. Beaulieu et al. Evolution clinique des patients atteints d'un cancer prostatique de risque intermediaire traites par implants permanents d'iode-125: l'experience de l'Hotel-Dieu de Quebec Cancer/Radiother 14 2010 183 188
30. H. Afsharpour, G. Landry, and M. D'Amours et al. ALGEBRA: Heterogeneous dosimetry algorithm based on GEANT4 for brachytherapy Phys Med Biol 57 2012 3273 3280
31. H. Afsharpour, B. Reniers, and G. Landry et al. Consequences of dose heterogeneity on the biological efficiency of 103Pd permanent breast seed implants Phys Med Biol 57 2012 809 823
32. J.Z. Wang, J.G. Rhee, and P. Shi et al. In vitro determination of radiation sensitivity parameters for DU-145 prostate cancer cells Int J Radiat Biol 84 2008 515 522 (Pubitemid 351878837)
33. O. Algan, C.C. Stobbe, and A.M. Helt et al. Radiation inactivation of human prostate cancer cells: The role of apoptosis Radiat Res 146 1996 267 275 (Pubitemid 26320090)
34. T.L. Deweese, J.M. Shipman, and L.E. Dillehay et al. Sensitivity of human prostatic carcinoma cell lines to low dose rate radiation J Urol 159 1998 591 598 (Pubitemid 28049287)